(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with metastatic castration-resistant prostate cancer (mCRPC). Two reviewers searched for publications from 1 January 2...

Descripción completa

Detalles Bibliográficos
Autores principales: von Eyben, Finn E., Kairemo, Kalevi, Paller, Channing, Hoffmann, Manuela Andrea, Paganelli, Giovanni, Virgolini, Irene, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392412/
https://www.ncbi.nlm.nih.gov/pubmed/34440246
http://dx.doi.org/10.3390/biomedicines9081042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392412/
https://www.ncbi.nlm.nih.gov/pubmed/34440246
http://dx.doi.org/10.3390/biomedicines9081042

Ejemplares similares